Related references
Note: Only part of the references are listed.UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan
Jean-Francois Cote et al.
CLINICAL CANCER RESEARCH (2007)
The role of SN-38 exposure, UGT1A1*28 polymorphism, and baseline bilirubin level in predicting severe irinotecan toxicity
Roshni P. Ramchandani et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2007)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients
E Cecchin et al.
CLINICAL CANCER RESEARCH (2005)
Cancer incidence and mortality in Europe, 2004
P Boyle et al.
ANNALS OF ONCOLOGY (2005)
Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer:: Results of a phase II study
J Taïeb et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Clinical anticancer drug development: targeting the cyclin-dependent kinases
C Benson et al.
BRITISH JOURNAL OF CANCER (2005)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Factors affecting cytochrome P-450 3A activity in cancer patients
SD Baker et al.
CLINICAL CANCER RESEARCH (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
V Charasson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Simple and sensitive high-performance liquid chromatography method for simultaneous determination of urinary free cortisol and 6β-hydroxycortisol in routine practice -: For CYP 3A4 activity evaluation in basal conditions and after grapefruit juice intake
E Rouits et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2003)
Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma
HR Dhaini et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Genetic contribution to variable human CYP3A-mediated metabolism
JK Lamba et al.
ADVANCED DRUG DELIVERY REVIEWS (2002)
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
JY Douillard et al.
LANCET (2000)
Share Paper
